Top Markets
#1 ALEO ALEO +7.58%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +5.79%
#3 TDCCP TDCCP +4.33%
#4 Cortex Cortex +4.27%
#5 Synapse Synapse +4.24%
#6 Steem Steem +3.89%
#7 MANTRA MANTRA +3.47%
#8 Moo Deng Moo Deng +3.47%
#9 Zilliqa Zilliqa +3.30%
#10 Ontology Gas Ontology Gas +3.07%
Coin of the day
ALEO ALEO
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Classifica tra le azioni #31262
Noxopharm Limited is an Australian drug development company with an... Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Prezzo delle azioni
$0.04443294
Capitalizzazione di mercato
$13.65M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-32.53%
Paese
AU
Scambia Noxopharm Limited (NOX)

Categoria

Healthcare
EPS per Noxopharm Limited (NOX)
EPS al June 2026 TTM: $-0.01
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Noxopharm Limited, l’EPS attuale della società (TTM) è $-0.01. Alla fine del 2024, la società aveva un EPS di $-0.01 una diminuzione rispetto a rispetto a quello del 2023, che era di $-0.03.
Storico EPS per Noxopharm Limited da 2016 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
2026 (TTM) $-0.01 8.00%
2025 $-0.01 35.80%
2024 $-0.01 -76.38%
2023 $-0.03 -22.40%
2022 $-0.04 66.79%
2021 $-0.03 1,792.86%
2020 0.00 -97.54%
2019 $-0.06 -48.69%
2018 $-0.11 314.55%
2017 $-0.03 66.46%
2016 $-0.02 0.00%
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -160,470.37%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 73,788.89%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 48,881.48%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -256,951.85%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH